Replimune stock.

Why Replimune Stock Is Soaring Today. ... Shares of Replimune Group (REPL-2.97%) were soaring 13.3% higher as of 11:01 a.m. EDT on Thursday after rising as much as 22.4% earlier in the day. The ...Stock Price Forecast The 9 analysts offering 12-month price forecasts for Replimune Group Inc have a median target of 48.00, with a high estimate of 70.00 and a low estimate of 32.00.Replimune Announces Pricing of Public Offering | Replimune BOSTON , Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group , Inc. (Nasdaq: REPL), a …Replimune's shares could be a promising option for shorting if the upcoming trial results are negative, as I believe is very likely. In this scenario, Replimune's stock could potentially fall by ...

Replimune Group Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-3.531 per share for the current fiscal year. Replimune Group Inc does not currently pay a dividend.

Stock USD 19.28 0.44 2.23% Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Replimune Group is 'Hold'

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ...Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 11.71 +0.53 (+4.74%) At close: 04:00PM EST 11.71 0.00 (0.00%) After hours: 04:20PM EST 1d 5d 1m...1,703.30 -8.20(-0.48%) Crude Oil 76.65 -0.52(-0.67%) Gold 1,943.70 +6.00(+0.31%) Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. …REPL Stock 12 Months Forecast. $57.33. (396.79% Upside) Based on 4 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $57.33 with a high forecast of $70.00 and a low forecast of $42.00. The average price target represents a 396.79% change from the last price of $11.54.A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ...

REPL Replimune Group Inc Nov 24 • 01:26PM ET 10.85 +0.56 5.49% Healthcare • Biotechnology • USA • NASD Stock Detail • Compare Perf. • Options Chain …

Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Replimune Group Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... For US and Canadian Stocks, the Overview page includes key statistics on the stock's fundamentals, with a link to see more.Stock Price Forecast The 9 analysts offering 12-month price forecasts for Replimune Group Inc have a median target of 48.00, with a high estimate of 70.00 and a low estimate of 32.00.13 Jul 2023 ... Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the ...Replimune Group Inc REPL Morningstar Rating Unlock Stock XNAS Rating as of Nov 29, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...Shares of Replimune Group Inc. (REPL) surged more than 46% to touch a new high of $46.28 in intraday trading on Wednesday after an analyst at Roth Capital Tony Butler hiked his price target on the ...Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ...

Nov 23, 2023 · In the past week, REPL stock has gone down by -7.80%, with a monthly decline of -26.02% and a quarterly plunge of -49.58%. The volatility ratio for the week is 8.63%, and the volatility levels for the last 30 days are 9.24% for Replimune Group Inc The simple moving average for the last 20 days […] To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ...Dec 7, 2022 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune Group Inc (REPL) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News DIA 0.02% 5.71% GST.X 26.01% SKL.X 34.16% KAS.X 1.70% KDA.X …Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …Nov 30, 2023 · Replimune Group stock has received a consensus rating of buy. The average rating score is and is based on 21 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Replimune ...

Real time Replimune Group (REPL) stock price quote, stock graph, news & analysis.

Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response. Oncolytic immunotherapy …Stock USD 19.28 0.44 2.23% Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Replimune Group is 'Hold'Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authority.In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 1,436,172 shares of its common stock from Replimune at the public offering price, less the ...Dec 7, 2022 · In addition, Replimune intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock from Replimune at the public offering price ... Dec 9, 2022 · In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share ...

Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.

Replimune Group's results for treatment of patients with cutaneous squamous cell carcinoma are expected in Q4 2023. Click here to read our take on REPL stock.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA. REPL - Replimune Group Inc - Stock screener for ... Replimune Group Stock Performance Shares of REPL stock opened at $11.71 on Monday. The company has a quick ratio of 12.76, a current ratio of 12.76 and a debt-to-equity ratio of 0.11.Replimune Group Stock Performance. Shares of REPL stock opened at $11.71 on Monday. The company has a market cap of $691.58 million, a price-to-earnings ratio of -3.80 and a beta of 1.46. The stock has a 50 day simple moving average of $13.43 and a 200-day simple moving average of $18.08.November 29, 2023. $11.32. 786,621. 1:1. $11.67. $11.95. $11.26. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown.Replimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer.Replimune ( REPL) shares fell early this month after the company disclosed in its latest 10Q filing that the FDA raised certain issues related to CERPASS, including those on study endpoints, for ...Replimune's shares could be a promising option for shorting if the upcoming trial results are negative, as I believe is very likely. In this scenario, Replimune's stock could potentially fall by ...Why Replimune Stock Is Soaring Today. 485%. Motley Fool Returns. Market-beating stocks from our award-winning analyst team. Stock Advisor Returns. 485% . S&P 500 Returns. 126%.Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.

Their REPL share price targets range from $34.00 to $70.00. On average, they anticipate the company's share price to reach $51.33 in the next year. This suggests …Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …During the last session, Replimune Group Inc (NASDAQ:REPL)’s traded shares were 0.83 million, with the beta value of the company hitting 1.46. At the end of the trading day, the stock’s price was $11.71, reflecting an intraday gain of 4.74% or $0.53. The 52-week high for the REPL share is $29.52, that puts it down -152.09 from that peak ...Dec 7, 2022 · In addition, Replimune intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock from Replimune at the public offering price ... Instagram:https://instagram. california property tax increase 2023scottrade .comnasdaq playartificial intelligence stocks list WOBURN, Mass. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present. July 31, 2023. private capital managementetsy stoock About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize … rental properties vs reits Feb 27, 2023 · Replimune ends selloff after FDA response to mid-stage cancer trial. Following four straight sessions of losses, oncology-focused biotech Replimune Group ( NASDAQ: REPL) added ~7% on Monday after ... Replimune | 9,469 followers on LinkedIn. Replimune's mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response.The stock of Replimune Group Inc (REPL) has gone up by 13.26% for the week, with a -15.10% drop in the past month and a -44.22% drop in the past quarter. The volatility ratio for the week is 7.61%, and the volatility levels for the past 30 days are 9.26% for REPL. The simple moving […]